The IASLC 2019 North America Conference on Lung Cancer offers a tremendous opportunity to market to one of the largest gatherings of researchers, clinicians and professionals in the field of lung cancer and thoracic oncology in North America. Increase your visibility and organization’s profile by becoming an Exhibitor at this outstanding and important conference.
Location: Exhibition & Poster Hall, B2 Level
|Friday, October 11||09:30 - 18:00|
|Saturday, October 12||09:15 - 12:30|
Amgen Oncology is searching for and finding answers to incredibly complex questions that will advance care and improve lives for cancer patients and their families. Our research drives us to understand the disease in the context of the patient's life – not just their cancer journey – so they can take control of their lives.
For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
Bayer is a global Life Sciences leader in cardiopulmonology, hematology, neurology, oncology and women’s health. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs. For more information, visit www.bayer.us.
At Boehringer Ingelheim we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
Guardant Health is a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Since its launch, Guardant360 has been used by more than 6,000 oncologists, over 50 biopharmaceutical companies and all 27 of the NCC Network centers.
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association’s membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
Inivata is a leader in liquid biopsy. Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients. Our lead product, InVisionFirst®-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients.
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. We’re determined to continue making life better for all those affected by cancer around the world. To learn more, please visit www.LillyOncology.com.
For more than a century, Merck has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, Merck continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.
The book tells the stories of 39 patients with incurable lung cancer. It aims to help patients, families, and healthcare providers understand the experience of living with cancer. The author is a family doctor, teacher, and researcher who is a stage 4 lung cancer patient himself. He is patient #40.
Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.
At Novartis, we are reimagining medicine to produce breakthroughs and address unmet needs for patients with devastating diseases, including genetic disorders and certain deadly cancers. These efforts are done in collaboration with scientists, physicians, academia, industry partners and patients.
Takeda is a patient-focused, innovation-driven global pharmaceutical company that builds on a distinguished 237-year history. Our mission is to strive towards better health and a brighter future for people worldwide through leading innovation in medicine. Takeda’s Global Oncology Business Unit endeavors to deliver novel medicines to patients with cancer worldwide through its commitment to science, breakthrough innovation and passion for improving the lives of patients. Visit TakedaOncology.com.
Tempus is bringing the power of artificial intelligence to healthcare by building the world’s largest library of molecular and clinical data and a platform to make that data accessible and useful. We provide genomic sequencing services and analyze molecular and therapeutic data at scale to empower physicians and researchers to make real-time, data-driven decisions.
International Association for the Study of Lung Cancer (IASLC)
sponsorship at iaslc.org
Phone: +1 720 598 1951
Fax: +1 720 325 2848
Keep up to date with Conference News & Alerts.